MedTrace Logo

Phase ǀ Study on Pancreatic Cancer Treated by CyberKnife

NCT02716207 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-05-14

No results posted yet for this study

Summary

The maximum tolerated dose on locally advanced unresectable pancreatic tumor treated with CyberKnife SBRT will be evaluated.

Conditions

  • Pancreatic Tumor

Interventions

DEVICE

CyberKnife

Radiation Therapy

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Huo Jun Zhang, MD., PH.D · Changhai Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02716207 on ClinicalTrials.gov